Abstract
γ-Amino butyric acid is an extremely important inhibitory neurotransmitter in the mammalian central nervous system and is essential for the overall balance between neuronal excitation and inhibition. It is well documented that GABA deficiency is associated with several important neurological disorders such as Huntingtons chorea, Parkinsons and Alzheimers disease and other psychiatric disorders, like anxiety, depression, pain, panic, or mania. Although, it is known that increasing the brain concentration of GABA prevents convulsions, the high polarity and flexible structure of this compound are probably responsible for its inefficiency as an anticonvulsant when administered orally or intravenously. To resolve this problem, GABA analogues are being designed. Over recent years, there has been increasing interest in the synthesis and pharmacological effect of new GABA derivatives, which can be considered as potent drugs in the treatment of neurodegenerative disorders.
Keywords: GABA analogues, neurological diseases, GABAergic receptors, cyclopropane derivatives
Current Medicinal Chemistry
Title: A Role of GABA Analogues in the Treatment of Neurological Diseases
Volume: 17 Issue: 22
Author(s): K. Gajcy, S. Lochynski and T. Librowski
Affiliation:
Keywords: GABA analogues, neurological diseases, GABAergic receptors, cyclopropane derivatives
Abstract: γ-Amino butyric acid is an extremely important inhibitory neurotransmitter in the mammalian central nervous system and is essential for the overall balance between neuronal excitation and inhibition. It is well documented that GABA deficiency is associated with several important neurological disorders such as Huntingtons chorea, Parkinsons and Alzheimers disease and other psychiatric disorders, like anxiety, depression, pain, panic, or mania. Although, it is known that increasing the brain concentration of GABA prevents convulsions, the high polarity and flexible structure of this compound are probably responsible for its inefficiency as an anticonvulsant when administered orally or intravenously. To resolve this problem, GABA analogues are being designed. Over recent years, there has been increasing interest in the synthesis and pharmacological effect of new GABA derivatives, which can be considered as potent drugs in the treatment of neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Gajcy K., Lochynski S. and Librowski T., A Role of GABA Analogues in the Treatment of Neurological Diseases, Current Medicinal Chemistry 2010; 17 (22) . https://dx.doi.org/10.2174/092986710791698549
DOI https://dx.doi.org/10.2174/092986710791698549 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design The Effect of Acori Graminei Rhizoma and Extract Fractions on Spatial Memory and Hippocampal Neurogenesis in Amyloid Beta 1-42 Injected Mice
CNS & Neurological Disorders - Drug Targets Past, Present and Future Drugs for the Treatment of Obsessive- Compulsive Disorder
Current Medicinal Chemistry Cellular Strategies to Combat Protein Misfolding: Intricate Role of Hsp70 in Stress Management
Current Chemical Biology Novel Genetic and Peptide-Based Strategies Targeting the Bcl-2 Family, an Update
Recent Patents on DNA & Gene Sequences Pharmacological Modulation of Caspase Activation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Vascular Component of Alzheimer`s Disease
Current Neurovascular Research Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions
Current Alzheimer Research Editorial (Hot Topic: Monoamine Oxidase as a Target in Medicinal Chemistry and Drug Discovery)
Current Topics in Medicinal Chemistry The Animal Models of Dementia and Alzheimer’s Disease for Pre-Clinical Testing and Clinical Translation
Current Alzheimer Research Perspectives in Nanomedicine-Based Research Towards Cancer Therapies
Current Nanoscience Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry Neuroprotector Effect of Daily 8-Minutes of High-Intensity Interval Training in Rat Aβ<sub>1-42</sub> Alzheimer Disease Model
Current Alzheimer Research Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Diabetic Theory in Anti-Alzheimer’s Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents
Current Medicinal Chemistry Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets Peroxisome Proliferator-Activated Receptor-α Activation Protects Brain Capillary Endothelial Cells from Oxygen-Glucose Deprivation-Induced Hyperpermeability in the Blood-Brain Barrier
Current Neurovascular Research Potential of Photobiomodulation to Induce Differentiation of Adipose- Derived Mesenchymal Stem Cells into Neural Cells
Current Stem Cell Research & Therapy